Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer

HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination with Lilly's late‑stage investigational next generation KRAS inhibitor olomorasib The collaboration is underpinned by narmafotinib's growing base of clinical evidence and a strong scientific rationale that FAK activation is a key driver of resistance to KRAS G12C inhibitors The collaboration further extends narmafotinib beyond pancreatic and ovarian cancer into NSCLC, broadening Amplia's clinical footprint and addressable opportunity Melbourne, Australia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has entered into a Clinical Trial Collaboration and Supply Agreement (“CTCSA”) with Eli Lilly & Company (“Lilly”), to evaluate the combination of Amplia's investigational FAK inhibitor, narmafotinib, with Lilly's investigational KRAS G12C inhibitor, olomorasib. The Phase 1b/2b clinical trial will evaluate the safety and efficacy of this novel targeted therapy combination as a second line treatment in patients with advanced stage non-small cell lung cancer (NSCLC).